Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 11.0x - 12.1x | 11.5x |
| Selected Fwd P/E Multiple | 13.8x - 15.2x | 14.5x |
| Fair Value | €3.95 - €4.36 | €4.16 |
| Upside | -1.3% - 9.1% | 3.9% |
| Benchmarks | - | Full Ticker |
| Almirall, S.A. | - | BME:ALM |
| Recordati Industria Chimica e Farmaceutica S.p.A. | - | BIT:REC |
| Cosmo Pharmaceuticals N.V. | - | SWX:COPN |
| Bausch Health Companies Inc. | - | DB:BVF |
| ALK-Abelló A/S | - | CPSE:ALKB |
| Faes Farma, S.A. | - | BME:FAE |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| ALM | REC | COPN | BVF | ALK B | FAE | |||
| BME:ALM | BIT:REC | SWX:COPN | DB:BVF | CPSE:ALKB | BME:FAE | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | -37.4% | 2.5% | NM- | NM- | NM- | 11.7% | ||
| 3Y CAGR | NM- | 2.6% | 83.2% | NM- | 55.0% | 10.6% | ||
| Latest Twelve Months | 126.4% | 7.0% | 1335.6% | 92.2% | 67.7% | 21.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 1.0% | 21.3% | 12.5% | -8.6% | 6.6% | 19.1% | ||
| Prior Fiscal Year | -4.3% | 18.7% | -11.6% | -6.8% | 10.1% | 19.4% | ||
| Latest Fiscal Year | 1.0% | 17.8% | 49.9% | -0.5% | 14.7% | 21.8% | ||
| Latest Twelve Months | 1.0% | 17.8% | 49.9% | -0.5% | 14.7% | 21.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 12.5x | 15.4x | 5.0x | 7.7x | 25.3x | 9.6x | ||
| Price / LTM Sales | 2.2x | 4.7x | 3.6x | 0.2x | 5.7x | 2.4x | ||
| LTM P/E Ratio | 211.8x | 26.4x | 7.2x | -51.8x | 38.9x | 11.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -51.8x | 26.4x | 211.8x | |||||
| Historical LTM P/E Ratio | 11.1x | 12.4x | 12.8x | |||||
| Selected P/E Multiple | 11.0x | 11.5x | 12.1x | |||||
| (x) LTM Net Income | 111 | 111 | 111 | |||||
| (=) Equity Value | 1,220 | 1,284 | 1,348 | |||||
| (/) Shares Outstanding | 311.2 | 311.2 | 311.2 | |||||
| Implied Value Range | 3.92 | 4.12 | 4.33 | |||||
| FX Rate: EUR/EUR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 3.92 | 4.12 | 4.33 | 4.00 | ||||
| Upside / (Downside) | -2.0% | 3.1% | 8.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ALM | REC | COPN | BVF | ALK B | FAE | |
| Value of Common Equity | 2,150 | 10,985 | 962 | 2,571 | 31,741 | 1,245 | |
| (/) Shares Outstanding | 213.5 | 206.3 | 16.0 | 367.9 | 221.2 | 311.2 | |
| Implied Stock Price | 10.07 | 53.25 | 60.09 | 6.99 | 143.50 | 4.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.05 | 1.08 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 10.07 | 53.25 | 57.30 | 6.46 | 143.50 | 4.00 | |
| Trading Currency | EUR | EUR | CHF | EUR | DKK | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.05 | 1.08 | 1.00 | 1.00 | |